*  Idiopathic Intracranial Hypertension Treatment Trial - Full Text View - ClinicalTrials.gov

Visual Field Outcomes for the Idiopathic Intracranial Hypertension Treatment Trial (IIHTT). Invest Ophthalmol Vis Sci. 2016 Mar ... Total treatment of IIH of more than two weeks (except for acetazolamide which is limited to 1 week). For every day on treatment ... Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor). Primary Purpose: Treatment. Official Title:. ... Factors Affecting Visual Field Outcomes in the Idiopathic Intracranial Hypertension Treatment Trial. J Neuroophthalmol. 2016 ...
https://clinicaltrials.gov/ct2/show/NCT01003639?cond="Pseudotumor cerebri"&rank=3

*  Substance Treatment and HIV Testing and Referral System - Full Text View - ClinicalTrials.gov

Primary Outcome Measures: *Referral Rates for Substance Abuse Treatment and HIV Testing [ Time Frame: Completed after 3500 pre- ... Secondary Outcome Measures: *Treatment Initiation [ Time Frame: 70 pre-STarS patients and 70 STaRS patients are enrolled, over ... Treatment Initiation Sub-Study. To test the effectiveness of STaRS on treatment initiation, 140 patients who receive referrals ... We will determine the rate of referrals and treatment initiation for 3,500 adult patients treated during treatment as usual ( ...
https://clinicaltrials.gov/show/NCT01488630?order=137

*  Pilot Study For Hypothermia Treatment In Hyperammonemic Encephalopathy In Neonates And Very Young Infants - Full Text View -...

Secondary Outcome Measures: *Time to normalization of ammonia level [ Time Frame: During the first 72 hours of treatment ]. One ... For these children to be able to benefit maximally from available long-term treatment and solid organ transplant, outcome of ... The treatment of neonates and very young infants in hyperammonemic coma is very complex and adding hypothermia therapy to this ... Primary Outcome Measures: *Number of Participants with unexpected Serious Adverse Events as a Measure of Safety and ...
https://clinicaltrials.gov/ct2/show/NCT01624311?term=Coma&rank=18

*  A Study to Evaluate ITCA 650 for the Treatment of Type 2 Diabetes in Patients With High Baseline HbA1c - Full Text View -...

Primary Outcome Measures: *Change in HbA1c between Week 39 and Day 0 [ Time Frame: 39 weeks ]. ... Primary Purpose: Treatment. Official Title:. An Open-Label Multi-Center Sub-Study to Evaluate the Efficacy, Safety and ... On stable treatment regimen of diet and exercise alone or in combination with a stable & optimal or near-optimal dose of ... A Study to Evaluate ITCA 650 for the Treatment of Type 2 Diabetes in Patients With High Baseline HbA1c. This study is ongoing, ...
https://clinicaltrials.gov/ct2/show/NCT01785771?term="Type 2 Diabetes"&lup_s=02/03/2013&lup_d=14&show_rss=Y&sel_rss=mod14

*  Far Infrared Irradiation for Control, Management and Treatment of Amyotrophic Lateral Sclerosis (ALS) - Full Text View -...

Primary Outcome Measures: *Therapy for ALS [ Time Frame: 2 years ]. Secondary Outcome Measures: *Rehabilitation of ALS patients ... Primary Purpose: Treatment. Official Title:. Phase 1 Study to Determine the Efficacy of Using Far Infrared Radiation for the ... Far Infrared Irradiation for Control, Management and Treatment of Amyotrophic Lateral Sclerosis (ALS). The recruitment status ... This study will investigate the use of far infrared radiation for the control, management and treatment of ALS. ...
https://clinicaltrials.gov/ct2/show/NCT00673140?term=Amyotrophic Lateral Sclerosis&rank=5

*  Treatment of Elderly Subjects With Psychosis and Behavioral Disturbances Associated With Dementia of the Alzheimer's Type ...

Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor). Primary Purpose: Treatment. Official Title:. ... Treatment of Elderly Subjects With Psychosis and Behavioral Disturbances Associated With Dementia of the Alzheimer's Type. This ... Primary Outcome Measures: *Brief Psychiatric Rating Scale (BPRS) Total Score [ Time Frame: 10 weeks ]. ... A Randomized, Double-Blind, Placebo-controlled, Efficacy, Safety, and Tolerability Study of Bifeprunox in the Treatment of ...
https://clinicaltrials.gov/ct2/show/NCT00160147

*  Second-line Treatment of HIV-1 With Ritonavir Boosted Atazanavir or Darunavir With an Optimized NRTI Backbone - Full Text View ...

Secondary Outcome Measures: *Proportion of subjects with HIV-1 RNA , 50 c/mL [ Time Frame: At week 24 ]. *Change from baseline ... Primary Purpose: Treatment. Official Title:. An Open-Label Phase 3B Study in HIV-Infected Individuals With Viremia on or After ... Second-line Treatment of HIV-1 With Ritonavir Boosted Atazanavir or Darunavir With an Optimized NRTI Backbone (SUPPRESS). This ... Primary Outcome Measures: *Proportion of subjects with Human immunodeficiency virus 1 (HIV-1) Ribonucleic Acid (RNA) , 50 c/mL ...
https://clinicaltrials.gov/show/NCT01605084?order=307

*  Bexarotene Amyloid Treatment for Alzheimer's Disease - Full Text View - ClinicalTrials.gov

Secondary Outcome Measuring Serum Biomarker Outcome Level Changes From Baseline to Week 4 in Beta amyloid1-40 and Beta amyloid1 ... Active Comparator: Bexarotene treatment Arm 75 mg of Bexarotene BID for week 1, then increasing to 150 mg BID for weeks 2 to 4. ... Secondary Outcome Measures: *Change in MMSE Score in ALL Subjects From Baseline to Week 4 [ Time Frame: Baseline to Week 4 ]. ... Primary Purpose: Treatment. Official Title:. A Double Blind Placebo Controlled Randomized Study to Evaluate the Efficacy and ...
https://clinicaltrials.gov/ct/show/NCT01782742

*  Smoking Treatment in HIV Clinical Care Settings - Full Text View - ClinicalTrials.gov

Primary Outcome Measures: *7 day point prevalence biochemically verified abstinence rates [ Time Frame: 3, 6, 9, and 12 months ... The treatments include face-to-face individual counseling, a computer-Internet-based self-help treatment and a self-help manual ... Self-help Manual plus nicotine replacment treatment.. Behavioral: self-help Participants receive a self-help manual and have ... Smoking Treatment in HIV Clinical Care Settings. This study has been completed. ...
https://clinicaltrials.gov/show/NCT00297453?order=658

*  PegIntron Versus Adefovir in the Treatment of Chronic Hepatitis B (CHB) e Antigen Positive Patients in Taiwan (P04498/MK-4031...

Primary Outcome Measures: *Number of Participants With a Combined Response Consisting of All Three Responses - (a) Serological ... The treatment phase will be 24 weeks for PegIntron and 48 weeks for adefovir. All subjects completing the assigned treatment ... at 48 weeks post PegIntron treatment for up to 24 weeks; for Adefovir, at 24 weeks post adefovir treatment for up to 48 weeks ... Primary Purpose: Treatment. Official Title:. An Open-Label, Randomized, Comparative Study With PegIntron vs. Adefovir in the ...
https://clinicaltrials.gov/show/NCT00371761

*  Long-term effectiveness of treatment with terbinafine vs itraconazole in onychomycosis: a 5-year blinded prospective follow-up...

OBJECTIVE: To examine long-term cure and relapse rates after treatment with continuous terbinafine and intermittent itraconazole in onychomycosis. DESIGN: Long-term prospective follow-up study. SETTING: Three centers in Iceland. SUBJECTS: The study population comprised 151 patients aged 18 to 75 years with a clinical and mycological diagnosis of dermatophyte toenail onychomycosis. INTERVENTIONS: In a double-blind, double-dummy study, patients were randomized to receive either terbinafine (250 mg/d) for 12 or 16 weeks or itraconazole (400 mg/d) for 1 week in every 4 for 12 or 16 weeks (first intervention). Patients who did not achieve clinical cure at month 18 or experienced relapse or reinfection were offered an additional course of terbinafine (second intervention). MAIN OUTCOME MEASURES: The primary efficacy criterion was mycological cure, defined as negative results on microscopy and culture at the end of follow-up and no requirement of second intervention ...
hirsla.lsh.is/lsh/handle/2336/31871

*  "Gastrointestinal complications associated with catheter ablation for a" by Lohit Garg, Jalaj Garg MD et al.

Atrial fibrillation is the most common arrhythmia in the United States. With the ageing population, the incidence and prevalence of atrial fibrillation are on the rise. Catheter ablation of atrial fibrillation is a widely accepted treatment modality in patients with drug refractory symptomatic paroxysmal or persistent atrial fibrillation. The close proximity to the left atrium posterior wall makes the thermosensitive esophagus a potential site of injury during catheter ablation of AF leading to various gastrointestinal complications. The major gastrointestinal complications associated with catheter ablation include atrioesophageal fistula, gastroparesis, esophageal thermal lesions and esophageal ulcers. Multiple studies, case reports and series have described these complications with various catheter ablation techniques such as radiofrequency, cryoenergy and high frequency focused ultrasound energy ablation. This review addresses the gastrointestinal complications after AF ablation ...
scholarlyworks.lvhn.org/medicine/1076/

*  Bi-weekly Cetuximab Combined With 5-fluorouracil/Leucovorin/Oxaliplatin (FOLFOX-6) in Metastatic Colorectal Cancer - Tabular...

For years the effective treatment of advanced colorectal carcinoma (CRC) was limited to fluorouracil (5-FU). Combination of 5-FU or a 5-FU analog with oxaliplatin, which has some antitumor activity as a single agent, shows synergistic activity. Combining oxaliplatin with a twice monthly folinic acid/5-FU schedule leads to a further improvement in first-line treatment of advanced CRC thus emerging to a standard regimen in first-line therapy of metastatic CRC.. Cetuximab is normally given as a weekly schedule. As recently shown a biweekly schedule with 500 mg/m² instead of the weekly standard regimen (initial dose of 400 mg/m² followed by 250 mg/m² every week) exhibits similar pharmacokinetic results with a comparable efficacy.. In order to improve the convenience for the patients, this study will evaluate the efficacy and safety of a bi-weekly combination of cetuximab with FOLFOX. Out of the various FOLFOX regimens the most convenient FOLFOX-6 schedule is chosen for the ...
https://clinicaltrials.gov/ct2/show/record/NCT01051167

*  A Clinical Randomized Trial to Evaluate the Safety of a Noninvasive Approach in High-Risk Patients Undergoing Major Vascular...

The concept of a beneficial effect of prophylactic coronary revascularization before major vascular surgery is based on the assumption that perioperative myocardial infarctions arise at locations in coronary arteries with hemodynamically critical stenosis, elicited by the stress of surgery. Preoperative coronary revascularization might prevent this devastating event and, in addition, improve long-term outcome. This hypothesis was supported by the CASS study that showed a reduced incidence of nonfatal myocardial infarctions after previous bypass surgery among vascular surgery patients compared with those treated medically (8.5% vs. 0.6%, p = 0.001) (4). More recently, the data from the BARI (Bypass Angioplasty Revascularization Investigation) trial showed that bypass surgery and PCI had similar low rates of postoperative cardiac events in noncardiac surgery (5). However, these studies were not designed to assign the optimal strategy in severely ill patients with extensive coronary artery ...
onlinejacc.org/content/49/17/1763

*  Factors affecting survival after concurrent chemoradiation therapy for advanced hepatocellular carcinoma: a retrospective study...

Since the protocol of CCRT for advanced stage HCC with portal invasion was introduced [11], favorable results have been reported; e.g., a median survival duration of ≥11 months [19, 22-24]. In the current study, the median OS for CCRT was 11.6 months. By comparison, in the Asian-Pacific sorafenib trial, which included Korean patients, the median OS durations with and without sorafenib were 6.5 and 4.2 months, respectively [7]. Although these results cannot be compared directly, the overall outcomes of CCRT seem to be more favorable than systemic treatment without localized treatment.. Although sorafenib is the recommended first-line treatment for advanced stage HCC per the BCLC staging system [8], in practice, its use is limited by its high cost, reimbursement strategy, modest survival gain, and poor tolerance. In cases in whichthe use of sorafenib is not feasible, we apply radiation-based treatment using a median radiation ...
ro-journal.biomedcentral.com.preview-live.oscarjournals.springer.com/articles/10.1186/s13014-017-0873-1

*  Prognosis in patients with low left ventricular ejection fraction after myocardial infarction. Importance of exercise capacity....

The measurement of left ventricular ejection fraction (LVEF) plays a key role in many strategies for managing patients after acute myocardial infarction. We tested the hypothesis that exercise capacity 1 month after myocardial infarction provides additional information in patients with a low LVEF and therefore assists in risk stratification. One hundred fifteen patients, with documented myocardial infarction and LVEF less than 35% by gated radionuclide scan 1 month after acute myocardial infarction, were followed up for 2 months to 7 years. Exercise capacity was estimated from a treadmill test 1 month after infarction. Using the Cox proportional hazards model, exercise capacity was a significant predictor of death or reinfarction. The relative risk of death, based on a comparison between the lowermost quintile (less than 4 METS) and uppermost quintile (greater than 7 METS), was 3.5 (95% confidence interval, 1.1-9.7); the relative risk in the fourth, third, and second quintile was 2.7, 2.1, and ...
circ.ahajournals.org/content/80/6/1636

*  Simultaneous coronary artery bypass grafting and carotid endarterectomy can be performed with low mortality rates - pdf download

Simultaneous coronary artery bypass grafting and carotid endarterectomy can be performed with low mortality rates. . Download books free in pdf. Online library with books, university works and thousands of documents available to read online and download.
books.duhnnae.com/2017/aug3/150181312457-Simultaneous-coronary-artery-bypass-grafting-and-carotid-endarterectomy-can-be-performed-with-low-mortality-rates.php

*  Running Injury Clinic | Predicting treatment outcome for runners with patellofemoral pain

The objective of this Project is to predict treatment outcome for injured runners using baseline gait biomechanics and patient reported outcome (PRO) data. In Canada, running is the number one recreational activity and has substantial benefits including improved quality of life (QoL), fitness, and health. However, each year 48%-65% of runners sustain a musculoskeletal (MSK) injury: the leading cause of disability for individuals under age 45. Patellofemoral pain (PFP) is the most common MSK injury with a combined direct and indirect cost of $145M-$182M per year in novice runners alone. PFP results in significantly reduced activity and QoL, along with an increased risk of chronic disease. Therefore, an interdisciplinary approach is critical to develop optimal treatment strategies to provide the right patients the right treatment at the right time.. ...
runninginjuryclinic.com/research/predicting-treatment-outcome-for-runners-with-patellofemoral-pain/

*  Paclitaxel-Coated Balloon for Recalcitrant In-Drug-Eluting Stent Restenosis | JACC: Cardiovascular Interventions

Complete percutaneous revascularization, including the treatment of complex lesions and chronic total occlusions, has become a frequent reality in interventional cardiology. Although the overall need for repeat revascularization due to drug-eluting stent (DES) restenosis remains in single-digit levels, in highly complex forms of coronary artery disease, it may significantly compromise the long-term outcomes (1). Use of a second layer of DES to treat in-DES-restenosis is feasible and efficacious, but safety concerns at very long-term follow-up have been raised (2). Paclitaxel-eluting balloons have been established as an equivalent alternative to repeat implantation of first-generation DES regarding the antirestenotic efficacy within the first year of treatment of in-DES restenosis (3,4).. In this issue of JACC: Cardiovascular Interventions, Rittger et al. (5) report 3-year results of the PEPCAD-DES (Treatment of Drug-Eluting Stent [DES] ...
interventions.onlinejacc.org/content/8/13/1701

*  Randomised phase I/II study to evaluate carbon ion radiotherapy versus fractionated stereotactic radiotherapy in patients with...

Recurrent gliomas remain a major challenge in radiation oncology. In the past, second courses of radiotherapy have only been applied reluctantly, in fear of treatment-related side effects. However, modern radiation techniques have enabled the radiation oncologist to deliver high local doses as an effective salvage treatment with low rates of side effects.. Especially for GBM, with unsatisfactory outcomes even after extensive research over the past centuries, effective treatment at tumor recurrence are needed urgently. With surgery and supportive care alone, overall survival is about 3-5 months. Postoperative RT can increase overall survival to 9-12 months [1]. A number of studies have shown that an additional treatment with chemotherapy can increase overall survival. This benefit, however, is commonly associated with a high risk of treatment-related side effects, especially with combination ...
https://bmccancer.biomedcentral.com/articles/10.1186/1471-2407-10-533

*  The impact of early postoperative pain on health-related quality of life - Zurich Open Repository and Archive

OBJECTIVES: To examine how the severity of postoperative pain affects patient's health-related quality of life (HRQoL) at 1 week following surgery and to compare two generic validated HRQoL instruments. METHODS: Patients undergoing general or orthopaedic surgery at the Royal London Hospital were randomly sampled. The following patient outcome data were collected EQ-5D (EuroQoL) pre-operatively and the Revised American Pain Society Patient Outcome Questionnaire (APS-POQ-R) at 24 hours postoperation; and EQ-5D, Short-Form-12 (SF-12) and APS-POQ-R at 7 days postoperation. The degree of association between pain and HRQoL was assessed using Pearson's correlation coefficient and multivariate generalized linear regression models. RESULTS: Of the 228 patients included, 166 patients provided data at 7 days. Sixteen percent reported severe pain ≥ 50% of the day at 7 days. The severity of pain on both the APS-POQ-R pain severity and interference and affective impairment domains at 7 ...
zora.uzh.ch/id/eprint/87534/

*  OP0223 Abatacept in the treatment of active psoriatic arthritis: 1-year results from a phase iii study | Annals of the...

Methods Pts with active disease (≥3 swollen and ≥3 tender joints), ≥2 cm target lesion of plaque psoriasis and inadequate response/intolerance to ≥1 non-biologic DMARD were randomized (1:1) to SC ABA 125 mg weekly or PBO for 24W, followed by open-label (OL) SC ABA up to 52W. Randomization was stratified by MTX use, prior TNF inhibitor (TNFi) use and skin involvement ≥3% of body surface area. Pts without ≥20% improvement in joint counts at W16 were switched to OL ABA (early escape; EE) for 28W (total study time: 44W). Pre-specified exploratory endpoints included: ACR20/50/70 responses at W44; adjusted mean changes from baseline (BL) in DAS28 (CRP; post hoc analysis) and HAQ-DI at W44 and PsA-modified total Sharp/van der Heijde score (SHS) at W44 (EE pts)/W52 (non-EE pts); complete resolution of BL enthesitis and dactylitis at W44 (EE pts)/W52 (non-EE pts); and Psoriasis Area and Severity Index (PASI) 50/75 responses at W44. Analyses used the ITT population with non-responder ...
ard.bmj.com/content/76/Suppl_2/145.2

*  Continuous Versus Episodic Amiodarone Treatment for the Prevention of Permanent Atrial Fibrillation - Full Text View -...

Our hypothesis is that episodic amiodarone treatment (i.e. amiodarone treatment 1 month prior until 1 month after cardioversion) is associated with a lower morbidity and a higher quality of life compared to continuous prophylactic amiodarone treatment while atrial fibrillation is still effectively suppressed. The latter means that at the end of the study permanent atrial fibrillation is prevented in comparable percentage of patients (70%) in both treatment strategies. However, this will be accomplished at the cost of a higher number of electrical cardioversions (2-3) in the episodic treatment group compared to the continuous treatment group ...
https://clinicaltrials.gov/show/NCT00392431

*  The Year in Cardiovascular Surgery | JACC: Journal of the American College of Cardiology

The post-operative outcomes of 1,343 patients undergoing CABG with or without concomitant valve surgery between 1996 and 2005, and who received aprotinin, were compared with those of 6,776 patients who received aminocaproic acid and 2,029 patients who received no antifibrinolytic therapy (43). The mortality rate in the aprotinin group was 6.4%, compared with 2.4% in the aminocaproic acid group, and 2.2% for the group receiving no antifibrinolytic agent; after risk adjustment, the hazard ratio for death of patients treated with aprotinin compared with patients receiving no antifibrinolytic therapy or patients receiving aminocaproic acid was found to be 1.32 (95% CI: 1.12 to 1.55, p = 0.003) and 1.27 (95% CI: 1.10 to 1.46, p = 0.004), respectively. Aprotinin use was also associated with a larger risk-adjusted increase in serum creatinine (p , 0.0001).. Another retrospective database study published simultaneously reported a relative risk of in-hospital death of 1.32 (95% CI: 1.08 to 1.63) in a ...
onlinejacc.org/content/53/25/2389

*  Rhabdomyolysis during interferon-β 1a treatment | Journal of Neurology, Neurosurgery & Psychiatry

Interferon-β (IFN-β) is one of the most effective currently available treatments for multiple sclerosis. It has also been used in the therapy of viral diseases and certain malignancies, as has the other type I interferon IFN-α. Most frequent side effects are transient flu-like symptoms such as myalgia, chills, and headaches. We describe a patient with relapsing-remitting multiple sclerosis who developed acute rhabdomyolysis during IFN-β 1a treatment. After the medication was discontinued, the patient improved rapidly.. A 39 year old man with a history of first symptoms in April 2000 was diagnosed as having relapsing-remitting multiple sclerosis, supported by the demonstration of oligoclonal IgG bands in the CSF but not in the blood, and multiple white matter lesions in periventricular localisations on MRI. Treatment with 22 μg IFN-β 1a (Rebif™, Serono, Unterschleissheim, Germany) by subcutaneous injection three times weekly was initiated in October 2000 ...
jnnp.bmj.com/content/72/2/274.1

*  Accelerated Infusion of Streptokinase for the Treatment of Left-Sided Prosthetic Valve Thrombosis | Circulation

The overall response rate of 59% (70 of 119) with fibrinolytic therapy observed in the present study was substantially lower than that reported in the literature. These poor results occurred despite the fact that patients were treated at a tertiary-care center with a great deal of experience in diagnosing and managing PVT. Outcomes at smaller centers are likely to be worse. Consensus statements on the treatment of PVT and recent systematic reviews, however, suggest that the success rate with fibrinolytic therapy is at least 80%.4,6,20,21 On the basis of this high success rate, the American College of Cardiology/American Heart Association and American College of Chest Physicians guidelines recommend fibrinolytic therapy as first-line treatment for patients in good functional class with low thrombus burden and in all other patients if they are considered to be at high risk for surgery.3,5,7 Some others recommend fibrinolytic therapy as first-line therapy for ...
circ.ahajournals.org/content/120/12/1108.full

*  148 Diastolic dysfunction and functional mitral regurgitation are the main determinants of abnormal cardiopulmonary stress test...

Reverse remodelling presenting with apparent healing of Heart Failure patients at mid-long term follow-up after Cardiac Resynchronization Therapy. Vitali Serdoz, L.; Pinamonti, B.; Daleffe, E.; Zecchin, M.; Pecora, D.; Di Lenarda, A.; Cappato, R.; Sinagra, G. // European Journal of Heart Failure. Supplements;Jun2008, Vol. 7 Issue 1, p177 An abstract of the article "Reverse remodelling presenting with apparent healing of Heart Failure patients at mid-long term follow-up after Cardiac Resynchronization Therapy," by B. Pinamonti and colleagues is presented. ...
connection.ebscohost.com/c/abstracts/25768236/148-diastolic-dysfunction-functional-mitral-regurgitation-are-main-determinants-abnormal-cardiopulmonary-stress-test-elderly-patients-systolic-heart-failure

*  Efficacy and safety of long term entecavir in chronic hepatitis B treatment naïve patients in clinical practice.

Background and aims. Entecavir (ETV) is effective and safe in patients with chronic hepatitis B in the short term, but its long term efficacy and safety has not been established. Material and methods. We evaluated HBV DNA clearance, HBeAg/antiHBe and
biomedsearch.com/nih/Efficacy-safety-long-term-entecavir/24756007.html

*  Clinical benefit of glycoprotein IIb/IIIa blockade with abciximab is independent of gender | JACC: Journal of the American...

The primary end point for these trials was a composite of death from all cause, MI or reinfarction or severe myocardial ischemia requiring urgent revascularization by either PCI or coronary artery bypass grafting (CABG) within 30 days after randomization. A second end point was a composite of death, MI or urgent revascularization within six months after randomization. For the long-term follow-up at one year, mortality was used. End point classifications of clinical events committees, blinded to treatment assignment, were used for the final analysis. An end point of in-hospital, MI was defined by one of two criteria: new, clinically significant Q waves in two or more contiguous electrocardiographic leads or elevation in creatine kinase or its MB isoenzyme to at least three times the upper limit of normal. After discharge from the hospital, MI was defined by the occurrence of new Q waves in two or more contiguous electrocardiographic leads or an elevation of creatine kinase or its MB isoenzyme ...
onlinejacc.org/content/36/2/381

*  The clinical case for proton beam therapy | Radiation Oncology | Full Text

The treatment of prostate cancer with proton beam therapy is controversial. Current treatment options include prostatectomy, brachytherapy, and intensity modulated x-ray therapy, all of which are less costly than proton beam therapy.. Prospectively randomized clinical trials have demonstrated that higher doses of x-ray therapy result in improved survival and lower doses to the rectum and bladder result in lower risks of complications. A phase 3 study funded by the NHS Trust randomly assigned 225 men with prostate cancer to 2-dimensional (2-D) or 3-D conformal x-ray therapy [54]. The results of this study proved the principle that reducing the radiation dose to the rectum and bladder by using 3-D conformal techniques reduces the incidence of ≥grade 2 bowel toxicity (from 18% with 2-D to 8% with 3-D) and bladder toxicity (from 23% with 2-D to 20% with 3-D). A phase 3 dose-escalation study conducted by MD Anderson Cancer Center randomly assigned 301 patients to 70 Gy using 2-D ...
ro-journal.biomedcentral.com.preview-live.oscarjournals.springer.com/articles/10.1186/1748-717X-7-174

*  Gefitinib and Combination Chemotherapy in Treating Patients With Advanced or Recurrent Colorectal Cancer - Full Text View -...

OBJECTIVES:. I. Determine the safety of gefitinib, fluorouracil, leucovorin calcium, and irinotecan in patients with advanced or recurrent colorectal cancer.. II. Determine the major side effects of this regimen in these patients. III. Determine the response rate, progression-free survival, and overall survival of patients treated with this regimen.. IV. Correlate response and other measures of outcome with epidermal growth factor receptor expression and the expression of genes that impact upon pathways of fluoropyrimidine cytotoxicity in patients treated with this regimen.. OUTLINE: This is a non-randomized, open-label, multi-center study.. Patients receive oral gefitinib daily beginning on day 1, irinotecan IV over 90 minutes on days 1 and 15, and leucovorin calcium IV over 2 hours and fluorouracil IV over 3-5 seconds followed by a 22-hour infusion on days 1, 2, 15, and 16. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. ...
https://clinicaltrials.gov/ct2/show/NCT00052585

*  Abstract WP10: Prolonged Microcatheter-based Local Thrombolytic Infusion as a Salvage Treatment for Failed Endovascular...

Background: Transvenous endovascular treatment including combination pharmacological and mechanical modalities is reserved for patients with cerebral venous thrombosis (CVT) not responsive to standard anticoagulation. However, transvenous endovascular treatment may not always be successful in achieving recanalization.. Objective: To determine the effectiveness of prolonged microcatheter based local thrombolytic infusion in treatment of patients with CVT who achieved no or suboptimal recanalization with endovascular treatment.. Methods: Patients who underwent transvenous endovascular treatment for cerebral venous thrombosis at three hospitals were identified through local registries. The final response to treatment was assessed and prolonged microcatheter based local thrombolytic infusion was instituted in selected patients as second line treatment. Serial angiograms were performed to assess ...
stroke.ahajournals.org/content/48/Suppl_1/AWP10

*  Cardiac Assist Devices Global Market Segmented Into Ventricular Assist Devices, Intra-Aortic Balloon Pumps (IABPs) And Total...

ResearchMoz presents this most up-to-date research on 'Cardiac Assist Devices Global Segmented Into Ventricular Assist Devices, Intra-Aortic Balloon Pumps
https://medgadget.com/2017/02/cardiac-assist-devices-global-market-segmented-into-ventricular-assist-devices-intra-aortic-balloon-pumps-iabps-and-total-artificial-heart-from-2017-2019.html

*  Re-irradiation for oligo-recurrence from esophageal cancer with radiotherapy history: a multi-institutional study | Radiation...

Patients' characteristics are shown in Table 1. Median maximum lymph node diameter was 22 mm (range, 5-106 mm). Histological diagnosis in all of the patients in whom re-irradiation was performed was squamous cell carcinoma. Median total radiation dose for oligo-recurrence was 60 Gy (range, 18-70 Gy). Of the 33 patients, 7 patients received definitive radiotherapy with median dose of 60 Gy (range, 50-60 Gy) as an initial treatment for esophageal cancer, 9 patients received adjuvant radiotherapy with median dose of 40 Gy (range, 40-60 Gy), and the others received neoadjuvant radiotherapy with median dose of 30 Gy (range, 30-40 Gy). Eleven of the 33 patients with a past irradiation history underwent re-irradiation by a hyperfractionation method with 1.2 Gy/fraction. Therefore, the median calculated biological effective dose using the Linear-Quadratic (LQ) model with α/β = 10 Gy (BED10) in patients in whom re-irradiation was performed was significantly lower than the median BED10 in others ...
ro-journal.biomedcentral.com.preview-live.oscarjournals.springer.com/articles/10.1186/s13014-017-0882-0

*  急診筆記: 三月 2010

The primary endpoint was favorable neurological outcome (defined as Glasgow-Pittsburgh cerebral performance category 1 or 2) 1 month after arrest. Multiple logistic regression analysis revealed that favorable neurological outcome was significantly more likely for children who received bystander CPR than for those who did not (4.5% vs. 1.9%), for patients aged 1-17 years than for infants younger than 1 year (4.1% vs. 1.7%), for those with ventricular fibrillation as the initial rhythm than for those with other rhythms (20.6% vs. 2.3%), and for those with witnessed arrest (by family or others) than for those with unwitnessed arrest (6.7% and 10.3%, respectively, vs. 1.3%). In children aged 1-17 years, rates of favorable neurological outcome were significantly higher with conventional CPR than with compression-only CPR among patients with noncardiac causes of arrest (7.2% vs. 1.6%), but rates did not differ by type of CPR among patients with cardiac causes of ...
er119test.blogspot.com/2010/03/